Xylonix and Genecast Partner to Advance Cancer Metastasis Research

Singapore, Singapore Oct 31, 2024 – Xylonix, a rapidly growing Singapore-based pharmaceutical company focused on developing innovative oncology and immunology products, has formed a strategic partnership with Genecast, a leading cancer diagnostics company from Korea. This collaboration aims to advance the field of early precision cancer diagnostics and cancer metastasis research, utilizing Genecast’s cutting-edge ADPS-PCR technology.

Genecast’s Innovation in Cancer Diagnostics

Genecast’s ADPS (Allele Discriminant Polymerase System) technology represents a significant leap forward in cancer diagnostics. This PCR-based ultra-sensitive platform allows the detection of mutated cfDNA in blood with a sensitivity as low as 0.01%, making it the most sensitive mutated cancer detection blood test available. Genecast offers a comprehensive range of PCR-based oncogene mutation detection kits and cancer panel test kits, targeting key genes such as EGFR, BRAF, KRAS, PIK3CA, and others.

Transforming Cancer Metastasis Research

Xylonix believes that Genecast’s highly sensitive detection capability for identifying mutated cancer presence in blood will revolutionize and accelerate both clinical and non-clinical cancer metastasis and relapse research by reducing time and cost. Non-clinical cancer metastasis and relapse research in immune-competent test subjects was previously inaccessible to many scientists due to the lengthy time-to-outcome associated with technical, financial, and logistical challenges. By enabling sensitive quantification of mutated cancer cfDNA, a powerful predictor of distant metastasis[1], this technology promises to accelerate the timeline of metastasis and relapse research from months to weeks in non-clinical settings, and from years to months in clinical settings.

A Collaborative Partnership

Under the master cooperation agreement, Xylonix will provide support to Genecast in several key areas. This includes raising awareness and understanding of Genecast’s innovative diagnostics solutions through scientific and medical marketing initiatives. Additionally, Xylonix will offer expert guidance to optimize the clinical and non-clinical applications of the technology as part of their research advisory services. Finally, Xylonix will expand the reach of Genecast products through its established sales networks.

Impact on Global Cancer Research and Treatment

This partnership is poised to significantly impact global cancer research and treatment. By making highly sensitive mutation detection accessible through widely available PCR machines, we are democratizing advanced diagnostics and enabling more precise and timely interventions.

“We are excited to partner with Genecast, whose innovative ADPS technology perfectly aligns with our mission to combat highly metastatic cancers in IL6-high patients,” said Dr. Jinhyuk CHUNG, CEO of Xylonix. “If we can stop metastasis and relapse, cancer will be cured. This collaboration will not only enhance our oncology development success but also empower researchers across the world who share our vision toward that goal.”

“Genecast is enthusiastic about working with Xylonix to expand the use and availability of our ADPS to clinics and cancer researchers worldwide,” said Byung Chul LEE, CTO & Founder of Genecast. “Together, we can drive significant advancements in cancer detection and treatment.”

About Xylonix

Xylonix is a Singapore-incorporated pharmaceutical company dedicated to developing and marketing innovative treatments for disorders driven by post-COVID macrophage, including rhinosinusitis, long COVID, autoimmune disorders, and highly metastatic cancers. Our mission is to provide comprehensive solutions for prevention, symptomatic management, and cures against COVID-endemic disorders, improving patient outcomes worldwide. Our products are currently available in clinics and hospitals across Singapore, with recent expansions into Korea and the Philippines, and with further expansion plans into the USA, China, Japan, and India.

About Genecast

Genecast is a leading cancer diagnostics company based in Korea, known for its ADPS technology that enables ultra-sensitive detection of oncogene mutations with a specified sensitivity of MAF 0.01% in a syngeneic background. Genecast’s product portfolio includes a wide range of PCR-based mutation detection kits and cancer panel test kits for early detection and for precision oncology.

For more information, please contact:

Media Officer: Gregory Irving –

[1] Huang et al., Ther Adv Med Oncol. 2022. DOI: